DR. RAJASEKARAN BALAJI , DR. REDDY KARRI , PROF. MEENA RAMANATHAN , PROF. ANANDA BALAYOGI BHAVANANI ,PROF. LAKSHMI JATIYA, DR. SHANMUGAM LOKESH, DR. LOKESHMARAN ANANDRAJ, DR. SENKADHIRDASAN DAKSHINAMURTHY
DOI: https://doi.org/Background: Metabolic syndrome (MetS) increases the risk of renal dysfunction through mechanisms such as oxidative stress, endothelial injury, and low-grade inflammation. Despite pharmacotherapy, Decline in renal function remains a concern. Yoga, an integrative mind–body practice, has shown potential to modulate systemic inflammation and autonomic balance, thereby improving renal outcomes.
Objective: To evaluate the effect of Adjuvant Yoga Therapy (AYT) on renal function markers in patients with MetS when combined with Standard Medical Management (SMM).
Methods: In this open- label randomized controlled trial, 116 adults with MetS were allocated to SMM plus AYT (n=58) and SMM alone (n=58) for six months. Primary outcomes were change in serum urea and creatinine, measured at baseline, three, and six months. Analysis used repeated measures ANOVA and independent t-tests.
Results: Urea levels significantly declined in the AYT group but remained unchanged in SMM. Creatinine decreased by 13.6% in AYT but increased by 7.3% in SMM. Significant group × time interactions were observed for both outcomes.
Conclusion: Adjuvant yoga therapy demonstrated renoprotective benefits by decreasing urea and creatinine levels in MetS patients, suggesting its utility as a safe, low-cost, culturally acceptable adjunct to standard care.
